Brochures
Ace Therapeutics In Vitro and In Vivo Ischemic Stroke Models
Ace Therapeutics Ischemic and Photochemically-Induced Stroke Models-Rodents & NHPs
Stroke drug discovery and development is a complex, lengthy and costly process. Here is our comprehensive library of resources. You'll find brochures, scientific resources, technical notes, and other materials related to stroke.
The resources in our library allow us to help you understand your options and make critical decisions for your stroke research. Our experts are also ready to help and support your stroke drug development program.
Get an Instant Quote NowGet started by choosing the service category of your interest and enjoy roaming our resources.
Brochures
To showcase our expertise in stroke research, we’ve developed a series of informative brochures. We invite you to explore them for insights into our research services, technology platforms, and success cases. Whether you represent a pharmaceutical company or an academic institution, we offer tailored solutions designed to advance your stroke research initiatives.
Research Rescources
Our research resources focus on several key areas, including the pathophysiology of stroke, experimental models, therapy development. This wealth of knowledge will provide you with a solid foundation and strong support for your work in the field of basic research and preclinical studies for stroke. If you have an interest in these topics, we invite you to explore our research resources for the latest findings and cutting-edge information.
Technical Notes
The use and development of technology plays a crucial role in enhancing our comprehension of stroke mechanisms and fostering innovation in therapeutics. In our "Technical Notes," we have outlined a range of commonly employed technologies, including imaging techniques, genomics, and biomarker detection methods. These technologies provide researchers with powerful tools to help them explore various aspects of stroke in depth.
Stroke, also known as cerebral infarction, is a critical medical condition that compromises respiratory and cardiovascular function and causes severe neurological deficits. Globally, stroke is the second leading cause of death and a major cause of disability.
A stroke occurs when a blood vessel that carries oxygen and nutrients to the brain is either blocked by a clot or bursts (or ruptures). Stroke generally occurs through two mechanism, either ischemic, or hemorrhagic. Nearly 90% of strokes are ischemic, caused by blocked blood vessels, while the remaining cases are hemorrhagic, resulting from internal bleeding.
A stroke can lead to permanent brain damage, long-term disability, or even death. Symptoms may vary, ranging from mild weakness to paralysis or numbness on one side of the face or body.
Causes of Ischemic Stroke
Ischemic strokes are often triggered by blood clots, which may form for several reasons, including:
Causes of Hemorrhagic Stroke
Hemorrhagic strokes result from bleeding in the brain and can be triggered by:
At Ace Therapeutics, we provide customized models, target identification, and drug efficacy assessment for ischemic stroke research to improve the understanding of the pathomechanisms of ischemic stroke and the development of therapeutics.
Ace Therapeutics is at the forefront of preclinical hemorrhagic stroke research services, combining long-standing expertise with advanced scientific tools. Our approach enables the detection of nuanced responses in animal models, providing clear insight into the efficacy and safety of new therapeutics for hemorrhagic stroke.
The pathophysiology of stroke is complex and multifactorial. It involves multiple processes including excitotoxicity, calcium overload, oxidative stress, energy depletion, neuroinflammation, immune system activation, and blood-brain barrier (BBB) disruption. However, the mechanisms underlying their interconnections are not well understood. Therefore, there is an urgent need to explore the mechanisms of CNS tissue injury and death after stroke at the molecular, cellular, tissue, and systemic levels.
Ace Therapeutics can help clients to analyze the cellular and molecular mechanisms involved in stroke injuries and identify potential therapeutic targets.
Today, the standard of care for stroke includes aspirin regimens, recombinant tissue plasminogen activator (rtPA), and arterial recanalization techniques. rtPA is the only FDA-approved treatment for acute ischemic stroke, but has a low success rate and a limited time window for efficacy. Further research is needed to develop a drug that can effectively treat stroke.
At Ace Therapeutics, we are dedicated to helping clients develop different types of stroke drugs and evaluating the effects of treatment. Your stroke drug discovery program can move forward with reliable data and insights provided by our team of experts.
Post-stroke depression (PSD) is the most prevalent mood disorder that occurs
following a stroke, and it is a significant barrier to recovery and rehabilitation
for stroke.
Biological factors affecting the pathogenesis of PSD involve the site of
stroke, the type of stroke, the neurobiological pathways involved, mechanisms of
inflammation and apoptosis, and genetic factors.
Selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants
(TADs) have been widely used for PSD treatment.
Magnetic resonance imaging (MRI) can noninvasively detect brain tissue damaged by ischemic stroke and intracerebral hemorrhage within minutes of stroke onset.
The prognosis for hemorrhagic stroke is typically less favorable. Beyond the loss of brain cells, it significantly elevates the risk of severe complications, including heightened intracranial pressure and cerebral vasospasms.
The post-stroke neurogenic burst in subventricular zone (SVZ) and subgranular zone
(SGZ) niches may have differing effects on stroke outcomes. While enhancing SVZ
neurogenesis could aid functional recovery, increased hippocampal neurogenesis might
worsen post-stroke cognitive impairment.
Therefore, therapeutic strategies targeting neurogenesis should be
niche-specific, focusing on selectively modulating specific steps of the neurogenic
process rather than broadly altering the overall response.
View all of our contract services, including basic stroke research, experimental modeling and preclinical drug studies, and more.
View Our Pharmaceutical R&D ServicesOur customized preclinical testing services cover a broad range of therapeutic areas to support your early-stage stroke drug discovery.
View Our Stroke Research Areas